Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence.

Abstract

The role of neoadjuvant chemotherapy in variant histology bladder cancers has yet to be validated in randomized control trials. Several case series have reported experience with NAC in the setting of variant histology. PATIENT SUMMARY: We reviewed outcomes for patients with variant histology muscle-invasive bladder cancer who received chemotherapy before cystectomy. Outcomes varied significantly in the current literature. The best outcomes are associated with neoadjuvant chemotherapy (NAC) for small cell variants, while there is potential benefit with the use of NAC for squamous cell and adenocarcinoma variants.

• Authors: Siamak Daneshmand, Azadeh Nazemi
• Journal: European urology focus (Eur Urol Focus) Vol. 6 Issue 4 Pg. 639-641 (07 15 2020) ISSN: 2405-4569 [Electronic] Netherlands
• PMID: 32451316 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020. Published by Elsevier B.V.

Topics

• Chemotherapy, Adjuvant
• Cystectomy
• Humans
• Neoadjuvant Therapy
• Urinary Bladder Neoplasms (classification, drug therapy, pathology, surgery)